Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

VC Tally: $1.2bn Invested So Far In 2016 Includes Savara, Corvidia

This article was originally published in Scrip

Executive Summary

New biotechnology companies still are able to raise some fairly large Series A venture capital rounds, contributing to a whopping $1.2bn in VC investment for drug developers during the first two months of 2016, but most startups and early-stage firms still are moving along at a pretty standard fundraising pace.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register